Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6622376 | 0.89 | MEN1 (0.50) | MEN1KMT2ACES2CES1L3MBTL1 | |
| SCHEMBL10859938 | 0.86 | TDP1 (0.53) | MEN1KMT2ACES2CES1LMNA | |
| SCHEMBL2903284 | 0.85 | MEN1 (0.46) | MEN1KMT2ACES2CES1SMN1; SMN2 | |
| SCHEMBL3239706 | 0.82 | NPC1 (0.44) | MEN1KMT2ACES2CES1SMN1; SMN2 | |
| SCHEMBL15154014 | 0.82 | LMNA (0.40) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL11819176 | 0.82 | NPC1 (0.44) | MEN1KMT2ACES2CES1SMN1; SMN2 | |
| SCHEMBL15154021 | 0.77 | BCL9 (0.61) | MEN1KMT2ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL11358699 | 0.77 | RECQL (0.46) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL150958 | 0.77 | AOC2 (0.41) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL2906150 | 0.76 | MIF (0.43) | MEN1KMT2AL3MBTL1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4200575-A | 7[(2-Thiazolyl)-2-(oxoimino)acetamido]cephalosporin derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1980-04-29 | — | — | US | claimed |
| US-8268772-B2 | Depot preparations | SYMRISE AG (DE) | 2012-09-18 | — | — | US | disclosed |
| EP-2217564-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XenoPort, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-19 | — | — | US | disclosed |
| WO-2009033054-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20060111269-A1 | Depot preparations | SYMRISE AG (DE) | 2006-05-25 | — | — | US | disclosed |
| US-20040235761-A1 | Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1417967-A1 | NOVEL VIRUS PROLIFERATION INHIBITION/VIRUCIDAL METHOD AND NOVEL PYRADINE NUCLEOTIDE/PYRADINE NUCLEOSIDE ANALOGUE | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-05-12 | — | — | EP | disclosed |
| US-4200575-A | 7[(2-Thiazolyl)-2-(oxoimino)acetamido]cephalosporin derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1980-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | ADSL, SLC19A1, SLC25A21 | MEN1 1102/4885KMT2A 4109/4885CES2 537/4885 |
| US-20040235761-A1 | Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue | CDK5, NT5C3B, CDK15 | MEN1 2916/4885KMT2A 1499/4885CES2 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.